Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614205 | 0.84 | MCHR1 (0.39) | MCHR1CYP2C19HTTRORCMAPK1 | |
| SCHEMBL12614203 | 0.84 | MCHR1 (0.39) | MCHR1CYP2C19HTTRORCMAPK1 | |
| SCHEMBL15578256 | 0.83 | PTGER4 (0.36) | EPHX2HRH3 | |
| SCHEMBL15577976 | 0.83 | HRH3 (0.41) | MCHR1HRH3 | |
| SCHEMBL15579258 | 0.82 | HRH3 (0.37) | MCHR1HRH3OPRM1 | |
| SCHEMBL16933681 | 0.80 | POLB (0.34) | HRH3 | |
| SCHEMBL16933538 | 0.78 | POLB (0.43) | CYP2C19HSD11B1IDO1OPRM1 | |
| SCHEMBL16933562 | 0.73 | MAPK1 (0.41) | CYP2C19MAPK1 | |
| SCHEMBL12614236 | 0.71 | UGCG (0.41) | MCHR1CYP2C19HTT | |
| SCHEMBL15578288 | 0.69 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | claimed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | claimed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | claimed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | claimed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | claimed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | claimed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12150938-B2 | Biomarker of polycystic kidney disease and uses thereof | GENZYME CORPORATION (US) | 2024-11-26 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117679415-A | Glucoamide synthase inhibitors | 建新公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3497/4885CYP2C19 2400/4885HTT 1005/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3497/4885CYP2C19 2400/4885HTT 1005/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | MCHR1 3620/4885CYP2C19 2156/4885HTT 1328/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3497/4885CYP2C19 2400/4885HTT 1005/4885 |
| US-12150938-B2 | Biomarker of polycystic kidney disease and uses thereof | PKD2, PKD1, KLKB1 | MCHR1 2545/4885CYP2C19 4862/4885HTT 3444/4885 |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3740/4885CYP2C19 2772/4885HTT 1079/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3740/4885CYP2C19 2772/4885HTT 1079/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MCHR1 3740/4885CYP2C19 2772/4885HTT 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.